Announcements

Welcome to Mofo Life Sciences

MoFo Life Sciences shares timely legal and business insights and in-depth analyses on trends and the complex technologies at the heart of the global pharmaceutical, biotechnology, diagnostics, medical devices, digital health, and AgTech fields.

February 05, 2019 - Announcements
Morrison & Foerster Opens Boston Office, Further Expanding Premier Technology and Life Sciences Capabilities
Morrison & Foerster, a leading global law firm, is pleased to announce that it has opened an office in Boston to further extend its market-leading technology and life sciences capabilities. The move also expands the firm’s premier Finance and Emerging Companies and Venture Capital (ECVC) practices. Additionally, the
... ›
January 26, 2019 - United States, Biotech, Pharma, Regulatory, Intellectual Property
Federal Circuit Corrects USPTO on Reasonable Efforts When Calculating Patent Term Adjustment
The Federal Circuit ruled on January 23, 2019, that the United States Patent and Trademark Office (“PTO”) erred in reducing the term of a patent owned by Supernus Pharmaceuticals by 546 days, during which time the company could not have furthered prosecution of the
... ›
January 25, 2019 - European Union, Pharma, Regulatory, Intellectual Property
A Structured Guide to Recent Case Law of the Court of Justice of the European Union on Supplementary Protection Certificates in Europe
By: Wolfgang Schönig
In principle, patents confer protection for a maximum of 20 years. In Europe, however, the patent terms for pharmaceutical products that meet the conditions necessary for supplementary protection certificates (“SPC”) can be extended for up to five years. Once a patent has been filed,
... ›
January 11, 2019 - Litigation, European Union, Pharma, Regulatory, Intellectual Property
The EU General Court’s Ruling on Pay for Delay
By: Wolfgang Schönig, Andreas Grünwald, Jens Hackl, Theresa Oehm and Robert Grohmann
The EU General Court (“Court”) reduced the fines imposed on Servier SAS and its subsidiaries (“Servier”) from a total of €428 million to €315 million (see press release no. 194/18), thereby partially annulling a European Commission (“Commission”) decision. The Court confirmed the Commission’s finding that
... ›
January 08, 2019 - United States, Biotech, Intellectual Property
A New Year's Gift for Patent Applicants?
By: Jonathan Bockman, Christopher Gloria and Karen G Potter Ph.D.
The USPTO rang in the new year by releasing new Examiner Guidance that could potentially benefit patent applicants who have previously encountered difficulty acquiring patents under the Office’s procedures for determining patent subject matter eligibility under 35 U.S.C. § 101. Supreme Court decisions regarding § 101
... ›
December 05, 2018 - European Union, Regulatory, Intellectual Property
IP Protection Post-Brexit: A Right-by-Right Analysis
By: Alistair Maughan, Wolfgang Schönig, Sana Ashcroft and Robert Grohmann
The United Kingdom is set to leave the European Union on 29 March 2019 (“Exit Date”). With Brexit fast approaching, on 25 November 2018 the EU and the UK announced their consensus on a withdrawal agreement that sets out the terms of the UK's
... ›
December 02, 2018 - Global, Agtech, Regulatory, Intellectual Property
Planting the Seeds of Change
By: Michael Ward Ph.D., Liz Freeman Rosenzweig Ph.D. and Liz Newman Ph.D.
Morrison & Foerster partner Michael R. Ward explained the specialized versions of IP law that have been developed for new plants in his article for Intellectual Property Magazine , “Planting the seeds of change.” “…plants are unlike other inventions in that they can often
... ›
November 27, 2018 - United States, Employment
Are Employee Non-Solicitation Clauses Still Legal In California?
By: Lloyd Aubry
The Fourth District Court of Appeals in San Diego on November 1, 2018, issued AMN Healthcare Inc. v. Aya Healthcare Services Inc. , in which it called into question the continuing viability in California of employee non-solicitation clauses found in many employment contracts and
... ›
November 09, 2018 - AI + Robotics, United States, Regulatory, Data Analytics, Intellectual Property
Patenting Artificial Intelligence in the U.S. – Considerations for AI Companies
By: Jonathan Bockman and Anna Yuan
Artificial intelligence (AI) encompasses technologies that have become increasingly relevant — and strategically important — to companies of all sizes across a wide range of fields. For example, AI technologies such as computer vision are critical to the operation of autonomous vehicles and pick-and-place
... ›
October 30, 2018 - United States, Biotech, CFIUS, Pharma, Regulatory
New CFIUS Pilot Program: What Life Sciences Companies and Investors Need to Know
By: Robert S. Litt and Joseph A. Benkert
As many life sciences companies and investors are aware, the U.S. Department of the Treasury (“Treasury”) recently announced a new “pilot program” for the Committee on Foreign Investment in the United States (“CFIUS”) effective November 10, 2018. The pilot program implements certain provisions of
... ›

Never miss a post from MoFo Life Sciences. Enter your email below to stay up-to-date.

Welcome to Mofo Life Sciences

Morrison & Foerster Opens Boston Office, Further Expanding Premier Technology and Life Sciences Capabilities

Federal Circuit Corrects USPTO on Reasonable Efforts When Calculating Patent Term Adjustment

A Structured Guide to Recent Case Law of the Court of Justice of the European Union on Supplementary Protection Certificates in Europe

By: Wolfgang Schönig

The EU General Court’s Ruling on Pay for Delay

By: Wolfgang Schönig, Andreas Grünwald, Jens Hackl, Theresa Oehm and Robert Grohmann

A New Year's Gift for Patent Applicants?

By: Jonathan Bockman, Christopher Gloria and Karen G Potter Ph.D.

IP Protection Post-Brexit: A Right-by-Right Analysis

By: Alistair Maughan, Wolfgang Schönig, Sana Ashcroft and Robert Grohmann

Planting the Seeds of Change

By: Michael Ward Ph.D., Liz Freeman Rosenzweig Ph.D. and Liz Newman Ph.D.

Are Employee Non-Solicitation Clauses Still Legal In California?

By: Lloyd Aubry

Patenting Artificial Intelligence in the U.S. – Considerations for AI Companies

By: Jonathan Bockman and Anna Yuan

New CFIUS Pilot Program: What Life Sciences Companies and Investors Need to Know

By: Robert S. Litt and Joseph A. Benkert